FilingSEC EDGAR8-K
Aptevo Announces Manufacturing Optimization and 2027 IND Enabling Study Plans for Trispecific Candidate APVO451
· SEC accepted
StagePreclinical
Filing content
Aptevo Therapeutics is optimizing manufacturing for its lead trispecific candidate, APVO451, and expects to initiate IND-enabling studies in 1H2027.
AI summary of the filing. Please also check the source.Related companies
Analyzed by WAPE AI.
Preparing English content…
Comments —
Loading comments…